Streptococcal A vaccine - ID Biomedical

Drug Profile

Streptococcal A vaccine - ID Biomedical

Alternative Names: GAS vaccine - ID Biomedical; StreptAvax

Latest Information Update: 01 Feb 2008

Price : $50

At a glance

  • Originator University of Tennessee
  • Developer ID Biomedical Corporation; National Institute of Allergy and Infectious Diseases; University of Tennessee
  • Class Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Streptococcal infections

Most Recent Events

  • 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
  • 18 Oct 2005 Data presented at the 43rd Annual Meeting of the Infectious Diseases Society (IDSA-2005) have been added to the adverse events and Bacterial infections immunogenicity sections
  • 28 Jan 2005 Clinical data from a media release have been added to the Bacterial infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top